Roche oral drug shown to keep breast cancer at bay, boosting shares<\/p>\n
Roche\u2019s\u00a0experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast cancer after surgery, boosting the company\u2019s shares and underpinning its traditional credentials in oncology.<\/p>\n
\u00a0<\/p>\n
The Swiss drugmaker said on Tuesday that a scheduled interim analysis of a late-stage trial showed the experimental pill resulted in a clinically meaningful improvement in keeping patients disease-free after surgery compared with standard endocrine therapy.<\/p>\n
\u00a0<\/p>\n
More details are to be published at a medical conference to be announced as Roche works towards regulatory approval, the company added.<\/p>\n
\u00a0<\/p>\n
The prospect of the drug reducing the spread of early-stage disease to other body parts lifted the company\u2019s share price by 6.1% to an eight-month high of 304.90 Swiss francs ($383.23) by 0939 GMT, with JPMorgan analysts calling the news a significant positive surprise.<\/p>\n
\u00a0<\/p>\n
If approved, the clinical use explored in the trial could generate about $5 billion in annual revenue, the analysts added.<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Roche oral drug shown to keep breast cancer at bay, boosting shares Roche\u2019s\u00a0experimental oral drug giredestrant has been…\n","protected":false},"author":2,"featured_media":26207,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[207,3517,265,134],"class_list":{"0":"post-26206","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-breast-cancer","9":"tag-giredestrant","10":"tag-oncology","11":"tag-roche"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116178710824639236","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/26206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=26206"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/26206\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/26207"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=26206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=26206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=26206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}